Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 28Genitourinary 7Thoracic 6Dermatologic 6Breast 6Head & Neck 5Gastrointestinal 4Other solid neoplasm 2Sarcoma 1NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 52Gastro-enteropancreatic neuroendocrine tumor 10Carcinoma, Neuroendocrine 8Small Cell Lung Carcinoma 6Adenoma, Islet Cell 6Colorectal Neoplasms 5Carcinoma, Merkel Cell 4Pancreatic Neoplasms 3Cholangiocarcinoma 3Carcinoma, Hepatocellular 3Carcinoid Tumor 3Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Stomach Neoplasms 2Sarcoma 2Salivary Gland Neoplasms 2Pheochromocytoma 2Paraganglioma 2Neoplasms, Unknown Primary 2Neoplasms 2Microsatellite Instability 2Mesothelioma 2Lung Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Medullary 2Brain Neoplasms 2Biliary Tract Neoplasms 2Vulvar Neoplasms 1Vipoma 1Urinary Bladder Neoplasms 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Ovarian Epithelial × NET × Clear all
NCT05199272 2024-11-15

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

23andMe, Inc.

Phase 1/2 Active not recruiting
141 enrolled
EndocrineGenitourinaryGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡